| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.40▲ | 8.41▲ | 8.41▲ | 8.11▲ | 8.77▼ |
| MA10 | 8.43▼ | 8.40▲ | 8.34▲ | 8.17▲ | 11.00▼ |
| MA20 | 8.43▼ | 8.32▲ | 8.19▲ | 8.66▼ | 11.71▼ |
| MA50 | 8.40▲ | 8.14▲ | 8.09▲ | 11.06▼ | 32.64▼ |
| MA100 | 8.31▲ | 8.11▲ | 8.30▲ | 11.79▼ | 34.10▼ |
| MA200 | 8.17▲ | 8.37▲ | 9.83▼ | 25.69▼ | 27.75▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | 0.002▲ | 0.028▲ | 0.112▲ | 0.830▲ |
| RSI | 50.157▲ | 62.521▲ | 66.494▲ | 35.106▼ | 25.911▼ |
| STOCH | 14.103▼ | 66.047 | 83.182▲ | 43.895 | 19.120▼ |
| WILL %R | -69.231 | -28.125 | -16.514▲ | -58.491 | -89.078▼ |
| CCI | -44.086 | 46.285 | 84.349 | 16.959 | -132.625▼ |
|
Wednesday, October 07, 2026 02:29 PM
Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced ...
|
|
Friday, October 02, 2026 03:35 AM
Novartis signed an Abogen licensing deal worth up to about $7.8 billion for ABO2203 and other potential RNA therapies, including $575 million upfront.
|
|
Friday, October 02, 2026 03:24 AM
Novartis (NYSE:NVS) has entered into a licensing agreement with Chinese biotechnology company Abogen covering an experimental RNA-based therapy and other potential treatments developed using Abogen’s ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/10/26 | 8.29 | 8.50 | 8.1348 | 8.40 | 208,348 |
| 08/10/26 | 8.15 | 8.325 | 7.965 | 8.26 | 649,309 |
| 07/10/26 | 7.95 | 8.13 | 7.93 | 7.93 | 91,812 |
| 06/10/26 | 8.00 | 8.07 | 7.78 | 7.99 | 411,686 |
| 05/10/26 | 7.83 | 8.105 | 7.63 | 7.97 | 258,282 |
| 02/10/26 | 8.22 | 8.4211 | 7.68 | 7.84 | 533,801 |
| 01/10/26 | 8.30 | 8.44 | 7.96 | 8.14 | 395,723 |
| 30/09/26 | 8.38 | 8.46 | 8.22 | 8.28 | 197,305 |
| 29/09/26 | 8.42 | 8.50 | 8.21 | 8.42 | 158,802 |
| 28/09/26 | 8.21 | 8.515 | 8.05 | 8.42 | 504,915 |
|
|
||||
|
|
||||
|
|